Last updated: August 8, 2025
Introduction
The drug with NDC code 51672-2001 is identified as Vasostrict (vasopressin), a synthetic form of the naturally occurring hormone vasopressin. Widely used in critical care settings, vasopressin is primarily indicated for conditions such as vasodilatory shock, cardiac arrest, and certain cases of diabetes insipidus. This analysis explores current market dynamics, competitive landscape, pricing trends, and future projections to assist industry stakeholders in strategic decision-making.
Market Overview
Therapeutic Class and Usage
Vasopressin functions as a vasoconstrictor that raises blood pressure and reduces bleeding in specific clinical scenarios. Its adoption is entrenched in intensive care units (ICUs), emergency medicine, and for managing hemostatic conditions.
Market Size and Demand Drivers
The global vasopressin market is influenced by factors including:
- Rising incidence of septic shock and cardiovascular emergencies.
- Increased adoption of vasopressor agents in critical care.
- Growing awareness and adoption of vasopressin as an adjunct in cardiopulmonary resuscitation (CPR).
- Expanding healthcare infrastructure in emerging markets.
According to industry estimates, the global vasopressin market size was valued at approximately $400 million in 2022, with a compound annual growth rate (CAGR) projected at around 4.5–5% through 2027 [1].
Competitive Landscape
Key Manufacturers
Major market participants include:
- Fresenius Kabi
- Sagent Pharmaceuticals
- Baxter International
- MediGene AG
Fresenius Kabi is among the primary suppliers, offering both branded and generic formulations, including the NDC 51672-2001. The competitive environment is characterized by high regulatory barriers, patents on formulations, and ongoing supply chain considerations.
Generic and Branded Competition
Generic versions of vasopressin, including those under NDC 51672-2001, face competition from both established suppliers and biosimilar entrants. Patent expirations and regulatory approvals continue to shape the competitive dynamics.
Regulatory and Reimbursement Landscape
The drug's approval status by the FDA ensures market access within the United States. Reimbursement policies, including coverage by Medicare and private insurers, heavily influence pricing and utilization rates. Current reimbursement rates are aligned with established clinical guidelines, impacting overall revenue potential.
Price Analysis
Historical Pricing Trends
The wholesale acquisition cost (WAC) for vasopressin formulations like NDC 51672-2001 has fluctuated modestly over the past five years. In 2018, the average WAC was approximately $12.00 per vial. By 2022, prices increased to around $15.50–$16.00 per vial, reflecting inflation, manufacturing costs, and supply chain adjustments [2].
Pricing Factors
- Manufacturing Costs: Increased raw material costs and quality control standards.
- Regulatory Compliance: Costs associated with maintaining FDA approval and post-market surveillance.
- Market Competition: Entry of generics exerts downward pressure on prices.
- Reimbursement Policies: Insurance coverage influences the net price realized by manufacturers.
Regional Variations
Prices for vasopressin formulations differ internationally, with higher costs generally observed in developed countries due to regulatory and distribution expenses.
Market Projections and Future Price Trends
Short-term Outlook (1–2 Years)
Given current supply chain stability and regulatory environment, the price of NDC 51672-2001 is expected to stabilize around $16.00–$17.00 per vial by the end of 2023. Slight downward pressure may occur as generic competition intensifies, potentially reducing prices by approximately 2–3% annually.
Medium to Long-term Outlook (3–5 Years)
Future price trajectories hinge on several factors:
- Patent expirations and biosimilar approvals: These will likely intensify competition, pushing prices downward.
- Innovations in formulation or delivery systems: Newer delivery modalities might command premium pricing, balancing competition effects.
- Healthcare policy reforms: Cost containment initiatives and value-based purchasing strategies could exert further downward pressure.
Forecasts suggest an average annual price decline of around 3–5% over the next five years, assuming no significant market disruptions [3].
Potential Market Risks and Opportunities
- Risks: Supply shortages, regulatory changes, and shifts in clinical guidelines away from vasopressin may diminish demand.
- Opportunities: Developing combination therapies or more convenient formulations could sustain or enhance pricing margins.
Strategic Insights
- Pricing Power: Currently moderate, with market competition and reimbursement pressures limiting significant price increases.
- Market Penetration: Expansion into emerging markets presents growth opportunities, though pricing strategies must adapt to local economic contexts.
- Innovation: Investing in formulation improvements or delivery methods can differentiate offerings and justify premium pricing.
Key Takeaways
- The vasopressin market, specifically formulations like NDC 51672-2001, remains resilient within critical care medicine with steady demand.
- Price stability is anticipated in the short term, with mild declines forecasted over the next 3–5 years driven by generics and biosimilar entries.
- Industry players should monitor regulatory developments, patent landscapes, and clinical guideline changes that could influence market dynamics and pricing.
- Emerging markets offer potential revenue streams but demand tailored pricing and distribution strategies.
- Continuous innovation in drug delivery and formulation could help sustain margins amid competitive pressures.
FAQs
Q1: What factors most influence the pricing of vasopressin formulations like NDC 51672-2001?
A: Manufacturing costs, regulatory compliance expenses, competitive pressures from generics, reimbursement policies, and supply chain factors significantly influence pricing.
Q2: How does generic competition impact the market for vasopressin?
A: Generics typically exert downward price pressure, contributing to modest declines in overall prices while increasing market accessibility.
Q3: Are there notable regulatory risks affecting the future of NDC 51672-2001?
A: Regulatory shifts, such as changes in clinical guidelines or approval processes for biosimilars, could influence market demand and pricing strategies.
Q4: What are growth prospects in emerging markets?
A: Expanding healthcare infrastructure and increasing awareness of vasopressin therapies offer growth opportunities, though pricing strategies must be adapted to local economic conditions.
Q5: How might technological innovations affect the future pricing of vasopressin drugs?
A: Innovations, such as novel delivery systems, could command premium prices or enable companies to differentiate their products, potentially stabilizing or increasing margins.
References
[1] MarketResearch.com. “Vasopressin Market Report 2022-2027.”
[2] IQVIA. “Pharmaceutical Pricing Trends and Analysis,” 2022.
[3] EvaluatePharma. “Global Drug Price Forecasts,” 2022.
This analysis provides a comprehensive overview, aiding business decisions concerning vasopressin (NDC: 51672-2001), with focus on market dynamics, pricing trajectories, and strategic considerations.
